Clinical Trials Browser

INDUSTRY × HMPL-013 × Clear all

NCT07235293 2026-05-22

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06562543 2026-05-20

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Phase 4 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04164199 2026-05-08

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3 Active not recruiting

Advanced Malignancies

NCT06497985 2026-03-19

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07483684 2026-03-19

A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

Phase 3 Not yet recruiting

Gastrointestinal

HER2 IHC3+ Advanced Colorectal Cancer

NCT06992258 2026-03-17

FRUITION

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07384377 2026-02-03

JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan

Phase 3 Not yet recruiting

Gastrointestinal

HER2-positive Colorectal Cancer

NCT06195514 2026-01-30

Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)

No longer available

Gastrointestinal

Colorectal Neoplasms

NCT05867420 2026-01-27

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT05405595 2026-01-07

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT05565417 2025-10-16

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Phase 1/2 Active not recruiting

BreastGastrointestinalHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

NCT06199973 2025-07-17

Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Phase 3 Active not recruiting

Gastrointestinal

Advanced Colorectal Cancer

NCT04577963 2025-07-14

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/2 Terminated

52 enrolled 23 charts

BreastGastrointestinalGynecologic

Breast Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05848739 2025-05-11

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Phase 1 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT03903705 2025-04-06

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Phase 1/2 Completed

Other solid neoplasm

Advanced Solid Tumor

NCT04322539 2025-04-04

FRESCO-2

Phase 3 Completed

691 enrolled 26 charts 1 FDA

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT04716634 2025-03-25

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

Phase 2 Completed

84 enrolled 17 charts

Other solid neoplasm

Advanced Solid Tumors

NCT06584032 2025-01-07

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Phase 3 Recruiting

Endometrial Neoplasms

NCT03251378 2024-09-25

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

Phase 1 Completed

129 enrolled 32 charts

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Triple Negative Breast Neoplasms

NCT05368805 2022-10-06

Fruquintinib DDI Study With P-gp and BCRP Substrates

Phase 1 Completed

Gastrointestinal

Colorectal Neoplasms

NCT03976856 2021-03-03

Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03977090 2021-02-10

Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer

Phase 1 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT02196688 2020-06-16

Study of Fruquintinib in Patients With Metastatic Colorectal Cancer

Phase 2 Completed

71 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT01645215 2020-02-17

Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT01975077 2020-02-17

A Phase Ib Study of Fruquintinib in 3rd Line mCRC

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT02314819 2020-02-17

FRESCO

Phase 3 Completed

416 enrolled 1 FDA

Gastrointestinal

Colorectal Neoplasms

NCT02590965 2020-02-13

A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03684967 2019-11-19

Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

Phase 2 Withdrawn

Lung Neoplasms

NCT02976116 2019-11-15

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Completed

NSCLC

NCT02691299 2019-02-12

FALUCA

Phase 3 Completed

NSCLC